Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23054680 | 1.00 | CYP3A4 (0.42) | CYP3A4EHMT2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL17360655 | 0.94 | CYP3A4 (0.38) | CYP3A4EHMT2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23054749 | 0.78 | EHMT2 (0.44) | EHMT2ALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL24591708 | 0.75 | EHMT2 (0.36) | EHMT2KMT2ASMN1; SMN2 | |
| SCHEMBL24591674 | 0.75 | CYP3A4 (0.46) | CYP3A4ALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL8418363 | 0.75 | CYP3A4 (0.46) | CYP3A4ALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL17360665 | 0.71 | CYP3A4 (0.42) | CYP3A4ALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL8026282 | 0.71 | CYP3A4 (0.42) | CYP3A4ALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL5135057 | 0.70 | CYP3A4 (0.41) | CYP3A4ALDH1A1MAPTL3MBTL1KMT2A | |
| SCHEMBL30479506 | 0.70 | CYP3A4 (0.41) | CYP3A4ALDH1A1MAPTL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023224-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SOLID CANCER, CONTAINING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VASTHERA CO LTD (KR) | 2026-01-28 | — | — | EP | disclosed |
| US-20250345343-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SOLID CANCER COMPRISING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | VASTHERA CO. LTD. (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-3650026-B1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR DERIVATIVE THEREOF, OR PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PULMONARY HYPERTENSION, CONTAINING PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VASTHERA CO LTD (KR) | 2025-10-01 | — | — | EP | disclosed |
| EP-2958926-B1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO LTD (KR) | 2023-03-08 | — | — | EP | disclosed |
| US-20220323453-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SOLID CANCER COMPRISING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | VASTHERA CO. LTD. (KR) | 2022-10-13 | — | — | US | disclosed |
| EP-4023224-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SOLID CANCER, CONTAINING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VASTHERA Co. Ltd. (KR) | 2022-07-06 | — | — | EP | disclosed |
| CN-114641294-A | Pharmaceutical composition for preventing or treating solid cancer containing epidithiodioxopiprazine derivative or pharmaceutically acceptable salt thereof | 瓦西特拉有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-3650026-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR DERIVATIVE THEREOF, OR PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PULMONARY HYPERTENSION, CONTAINING PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | VASTHERA Co. Ltd. (KR) | 2020-05-13 | — | — | EP | disclosed |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | VASTHERA CO. LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | VASTHERA CO. LTD. (KR) | 2019-10-22 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-9765090-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2017-09-19 | — | — | US | disclosed |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO. LTD. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO. LTD. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | VASTHERA CO. LTD. (KR) | 2017-08-24 | — | — | US | disclosed |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-08-04 | — | — | US | disclosed |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2016-08-04 | — | — | US | disclosed |
| EP-2958926-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | Ewha University-Industry Collaboration Foundation (KR) | 2015-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323453-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SOLID CANCER COMPRISING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PDIA5, SCLY, SEC16A | CYP3A4 2792/4885EHMT2 1097/4885ALDH1A1 1205/4885 |
| US-20170239261-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | CYP3A4 2141/4885EHMT2 2773/4885ALDH1A1 1550/4885 |
| US-20160222031-A1 | EPIDITHIODIOXOPIPERAZINE COMPOUND OR ITS DERIVATIVES, AND THE USE THEREOF | PRDX1, PRDX2, PRDX5 | CYP3A4 2141/4885EHMT2 2773/4885ALDH1A1 1550/4885 |
| US-20250345343-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SOLID CANCER COMPRISING EPIDITHIODIOXOPIPERAZINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PDIA5, SCLY, SEC16A | CYP3A4 2792/4885EHMT2 1097/4885ALDH1A1 1205/4885 |
| US-10450327-B2 | Epidithiodioxopiperazine compound or its derivatives, and the use thereof | PRDX1, PRDX2, PRDX5 | CYP3A4 2141/4885EHMT2 2773/4885ALDH1A1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.